Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-993 for Acute Pain After a Bunionectomy
NCT06619847Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VX-993 in acute pain (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Time-weighted Sum of Pain Intensity Difference at 48 hours. Started Oct 2024; status: completed.
02
Drugs
VX-993
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT06619847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619847.